Ling Ni

Title: Ling Ni - Innovator in Allergy and Asthma Treatment

Introduction

Ling Ni is a prominent inventor based in Dallas, TX (US). She has made significant contributions to the field of immunology, particularly in the treatment of allergies and asthma. Her innovative work focuses on enhancing immune responses to improve patient outcomes.

Latest Patents

Ling Ni holds a patent titled "Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)." This invention includes compositions and methods for enhancing Th1/Th17 cell responses while decreasing Th2 cell responses. The patent describes the activation of human dendritic cells and the enhancement of antigen-specific T cell responses in Dectin-1-expressing human dendritic cells. It involves the use of an anti-Dectin-1-specific antibody or fragment fused with one or more antigens. Additionally, TLR2 ligands may be included to further enhance activation and T-cell responses. The invention also outlines methods for treating allergies and asthma based on these compositions.

Career Highlights

Ling Ni is affiliated with the Baylor Research Institute, where she continues her research and development efforts. Her work has garnered attention for its potential to transform the treatment landscape for allergy and asthma patients.

Collaborations

Ling Ni collaborates with notable colleagues, including SangKon Oh and Jacques F. Banchereau. These partnerships enhance her research capabilities and contribute to the advancement of her innovative projects.

Conclusion

Ling Ni is a dedicated inventor whose work in allergy and asthma treatment showcases her commitment to improving health outcomes through innovative research. Her patent reflects her expertise and the potential impact of her contributions in the medical field.